Segment Reporting

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Reporting

Note 14 – Segment Reporting

In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy. The financial results of the Company’s operations are managed and reported to the Chief Executive Officer who is considered the Company’s chief operating decision maker (CODM), on a consolidated basis.

The CODM assesses performance and allocates resources based on the Company’s consolidated statements of operations and key components and processes of the Company’s operations are managed centrally. Segment asset information is not used by the CODM to allocate resources.

As a single reportable segment entity, the Company’s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:

	Year Ended December 31,
	2024			2023
Segment expenses
Salaries and benefits	$	15,282,537		$	16,979,251
Professional fees		4,819,562			5,530,998
General administrative expenses		1,438,833			1,689,772
Clinical development expenses		8,299,589			12,055,623
Other development expenses		6,480,674			6,789,590
Total operating and segment expenses	$	36,321,195		$	43,045,234
Interest income		2,514,816			2,902,939
Interest expense		(4,673,174	)		(4,205,922	)
Benefit from income taxes		869,169			1,406,019
Segment and consolidated net loss	$	(37,610,384	)	$	(42,942,198	)